CytomX Therapeutics (CTMX) Interest Expenses (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Interest Expenses came in at $25000.0 in Q4 2025, down 99.98% YoY from $162.1 million in Q4 2024, and down 99.5% on a QoQ basis from $5.0 million in Q3 2025.
CytomX Therapeutics (CTMX) Interest Expenses (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 12 years of Interest Expenses data on file, last reported at $25000.0 in Q4 2025.
- Quarterly Interest Expenses fell 99.98% year-over-year to $25000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 74.33% YoY) and the FY2025 annual result came in at $24.6 million, down 84.83% from the prior year.
- Interest Expenses retreated to $25000.0 in Q4 2025, from $5.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $175.5 million in Q4 2023 to a low of $25000.0 in Q4 2025.
- A 5-year average of $21.2 million and a median of $3.4 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses surged 7528.43% — and 2025, when it tumbled 99.98%.
- Tracing CTMX's Interest Expenses over 5 years: stood at $1.3 million in 2021, then surged by 75.71% to $2.3 million in 2022, then surged by 7528.43% to $175.5 million in 2023, then decreased by 7.61% to $162.1 million in 2024, then slumped by 99.98% to $25000.0 in 2025.
- The last three Interest Expenses figures came in at $25000.0 (Q4 2025), $5.0 million (Q3 2025), and $5.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 5.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.70 Mn |
| Jun 30, 2026 | 5.70 Mn |
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Sep 30, 2025 | 5.00 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.10 Mn |
| Jun 30, 2025 | 5.10 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 162.11 Mn |
| Dec 31, 2024 | 162.11 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Mar 31, 2024 | 3.90 Mn |
| Mar 31, 2024 | 3.90 Mn |
| Dec 31, 2023 | 175.45 Mn |
| Dec 31, 2023 | 175.45 Mn |